Cooper Financial Group Has $591,000 Stake in Regeneron Pharmaceuticals, Inc. $REGN

Cooper Financial Group boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,127 shares of the biopharmaceutical company’s stock after purchasing an additional 369 shares during the quarter. Cooper Financial Group’s holdings in Regeneron Pharmaceuticals were worth $591,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Saudi Central Bank bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Finally, Curat Global LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on REGN. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an “outperform” rating in a report on Monday, August 4th. Citigroup reissued a “buy” rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a report on Monday, June 9th. Finally, Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price on the stock. in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Trading Up 6.7%

NASDAQ:REGN opened at $599.94 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,045.95. The firm’s fifty day moving average is $570.67 and its 200-day moving average is $568.93. The firm has a market cap of $63.59 billion, a P/E ratio of 15.12, a P/E/G ratio of 1.79 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the previous year, the company earned $11.56 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.